Cyclosporine targets PTEN-deficient cancer cells in a highly specific manner
- Summary
- Rodney Rothstein, Ph.D.
- Technology Benefits
- Offers a cancer therapeutic that is cancer-specific and minimizes damage to normal cellsOffers a therapeutics agent that specifically targets PTEN-deficient cellsUtilizes a therapeutic agent that is already used in the clinical setting Patent information:Patent (WO/2012/145426)Tech Ventures Reference: IR 2902
- Technology Application
- Cancer treatment in PTEN-deficient cancersCancer treatment to be used in combination with other cancer therapeuticsResearch tool for studying PTEN-deficient cancers Research tool for studying CypACyclosporine is an immunosuppressive drug, currently used in transplant patients.
- Detailed Technology Description
- Rodney Rothstein, Ph.D.
- *Abstract
-
None
- *Inquiry
- Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- 2902
- *Principal Investigator
-
- *Publications
- Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringner M, Borg A, Parsons R. "Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity" PNAS. 2007 May 1;104(18):7564-7569.
- Country/Region
- USA
For more information, please click Here
